Laurus Labs Past Earnings Performance
Past criteria checks 2/6
Laurus Labs has been growing earnings at an average annual rate of 11.3%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 16.5% per year. Laurus Labs's return on equity is 3.9%, and it has net margins of 3.2%.
Key information
11.3%
Earnings growth rate
11.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 16.5% |
| Return on equity | 3.9% |
| Net Margin | 3.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Laurus Labs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 50,408 | 1,606 | 6,399 | 0 |
| 31 Dec 23 | 49,821 | 1,879 | 6,320 | 0 |
| 30 Sep 23 | 53,320 | 3,678 | 6,244 | 0 |
| 30 Jun 23 | 56,834 | 5,637 | 6,074 | 0 |
| 31 Mar 23 | 60,406 | 7,901 | 5,995 | 0 |
| 31 Dec 22 | 60,845 | 9,176 | 5,786 | 0 |
| 30 Sep 22 | 55,684 | 8,683 | 5,532 | 0 |
| 30 Jun 22 | 51,960 | 8,374 | 5,291 | 0 |
| 31 Mar 22 | 49,356 | 8,275 | 5,043 | 0 |
| 31 Dec 21 | 49,227 | 8,937 | 4,899 | 0 |
| 30 Sep 21 | 51,823 | 10,128 | 4,685 | 0 |
| 30 Jun 21 | 51,177 | 10,532 | 4,537 | 0 |
| 31 Mar 21 | 48,135 | 9,836 | 4,380 | 0 |
| 31 Dec 20 | 42,407 | 7,971 | 4,190 | 0 |
| 30 Sep 20 | 36,819 | 5,977 | 4,068 | 0 |
| 30 Jun 20 | 32,555 | 4,120 | 3,866 | 0 |
| 31 Mar 20 | 28,317 | 2,553 | 3,554 | 0 |
| 31 Dec 19 | 26,277 | 1,883 | 3,452 | 0 |
| 30 Sep 19 | 24,276 | 1,326 | 3,257 | 0 |
| 30 Jun 19 | 23,035 | 923 | 3,112 | 0 |
| 31 Mar 19 | 22,919 | 938 | 3,037 | 0 |
| 31 Dec 18 | 22,170 | 957 | 2,942 | 0 |
| 30 Sep 18 | 21,665 | 1,127 | 2,901 | 0 |
| 30 Jun 18 | 21,168 | 1,453 | 2,800 | 0 |
| 31 Mar 18 | 20,562 | 1,676 | 2,699 | 0 |
| 31 Dec 17 | 19,687 | 1,917 | 2,870 | 0 |
| 30 Sep 17 | 19,954 | 2,019 | 2,772 | 0 |
| 30 Jun 17 | 19,733 | 2,014 | 2,673 | 0 |
| 31 Mar 17 | 19,046 | 1,881 | 2,349 | 0 |
| 31 Mar 16 | 17,776 | 1,337 | 1,983 | 0 |
| 31 Mar 15 | 13,266 | 684 | 1,748 | 0 |
| 31 Mar 14 | 11,597 | 972 | 1,473 | 0 |
Quality Earnings: 540222 has high quality earnings.
Growing Profit Margin: 540222's current net profit margins (3.2%) are lower than last year (13.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 540222's earnings have grown by 11.3% per year over the past 5 years.
Accelerating Growth: 540222's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 540222 had negative earnings growth (-79.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.1%).
Return on Equity
High ROE: 540222's Return on Equity (3.9%) is considered low.